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Sustained release biodegradable solid lipid microparticles: 
Formulation, evaluation and statistical optimization by response 
surface methodology
For preparing nebivolol loaded solid lipid microparticles 
(SLMs) by the solvent evaporation microencapsulation pro-
cess from carnauba wax and glyceryl monostearate, central 
composite design was used to study the impact of indepen-
dent variables on yield (Y1), entrapment efficiency (Y2) and 
drug release (Y3). SLMs having a 10–40 µm size range, with 
good rheological behavior and spherical smooth surfaces, 
were produced. Fourier transform infrared spectroscopy, 
differential scanning calorimetry and X-ray diffractometry 
pointed to compatibility between formulation components 
and the zeta-potential study confirmed better stability due 
to the presence of negative charge (–20 to –40 mV). The ob-
tained outcomes for Y1 (29–86 %), Y2 (45–83 %) and Y3 (49–86 %) 
were analyzed by polynomial equations and the suggested 
quadratic model were validated. Nebivolol release from 
SLMs at pH 1.2 and 6.8 was significantly (p < 0.05) affected 
by lipid concentration. The release mechanism followed 
Higuchi and zero order models, while n > 0.85 value (Kors-
meyer-Peppas) suggested slow erosion along with diffu-
sion. The optimized SLMs have the potential to improve 
nebivolol oral bioavailability.
Keywords: central composite design, differential scanning 
calorimetry, solid lipid microparticles, microencapsula-
tion, nebivolol, carnauba wax
 
Cardiovascular diseases such as hypertension cause millions of deaths every year and 
hypertension may further cause congestive heart failure, myocardial infarction, stroke and 
renal diseases (1). Lifestyle modifications alone cannot manage hypertension and patients 
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have to rely on pharmacological intervention. The existing conventional drug delivery 
systems for such diseases cannot yield optimal therapeutic responses and fluctuation or 
dose missing may occur. This situation surely demands sustained drug delivery for 
achieving increased heart rate control (2).
Today, most pharmaceutical scientists are engaged in formulating an ideal oral drug 
delivery system that could offer controlled drug release to achieve the desired therapeutic 
outcome in an appreciably improved way (2). Oral sustained release formulations have 
been gaining ample consideration over the last three decades because of their significant 
therapeutic benefits such as flexibility in formulation, ease of administration and particu-
larly enhanced patient compliance. Microspheres, particularly based on natural biode-
gradable lipids (solid lipid microparticles) have attracted significant attention for offering 
sustained drug delivery (3–5).
SLMs exhibit enhanced physical stability, safety, biocompatibility; they improve drug 
aqueous solubility and provide higher plasma drug availability with improved membrane 
permeability (4–5). Moreover, they are characterized by dual loading ability (i.e. lipophilic 
and hydrophilic drugs) and are suitable and economical for large scale production (2). 
SLMs can prolong residence time at the absorption site (2) and can be formulated from 
solid lipids such as carnauba wax (CW) and glyceryl monostearate (GMS) because they 
exhibit excellent biocompatibility, biodegradability (4), lack of toxicity and ease of produc-
tion (4–6). CW and GMS SLMs can make drug release sustained and enhance drug bio-
availability (2–3). SLMs offer effective drug release control for a prolonged time period, 
causing a significant decrease in the number of doses and associated side effects, particu-
larly in patients with chronic diseases (5). Definitely, such chronic diseases like hyperten-
sion demand a sustained/controlled release drug delivery of a therapeutic agent to obtain 
better heart rate control and utilization of SLMs is found to be one of the most promising 
strategies among numerous available strategies for raising therapeutic compliance (3).
For the management of hypertension and to attain optimal therapeutic responses, 
β-blockers are considered a better option than other antihypertensive drugs, like calcium 
channel blockers, which cause rebound hypertension and cough and are considered as 
first line antihypertensive drugs (6). Compatibility of β-blockers with lipid excipients has 
been established (7) and some β-blockers such as propranolol (8), atenolol, metoprolol (8–
9), pindolol, labetolol (7) and carvedilol (9) have been encapsulated in solid lipid based 
polymers for oral (8, 10), topical (11), intranasal (12) and ophthalmic (13) routes of adminis-
tration. β-blockers have also been formulated in the form of mucoadhesive tablets contain-
ing propranolol loaded chitosan-gelatin microparticles (14–15).
Nebivolol (NEB) is a new third-generation highly selective β-blocker that causes va-
sodilatation through nitric oxide (NO) release and it is employed for the first-line manage-
ment of hypertension. NEB is highly effective and acceptable compared to other antihy-
pertensive agents but it demands frequent dosing due to its bioavailability (< 40 %) and 
plasma half-life (2 h). Low NEB oral bioavailability is a consequence of its poor solubility 
(6, 16). Hence, it demands improvement of solubility, dissolution and bioavailability (3) and 
the use of SLMs in this situation seems to be a better strategy compared to polymeric par-
ticles because SLMs can overcome the drawbacks like inefficient biodegradation, polymer 
accumulation effects and toxicity associated with polymeric microparticles (5).
The aim of the present study was to enhance NEB bioavailability by formulating sus-
tained release NEB-loaded SLMs using the solvent evaporation microencapsulation tech-
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nique. CW and GMS were used as release retarding materials because these lipophilic 
biomaterials are biodegradable and biocompatible, which makes them ideal candidates for 
this purpose. The effect of formulation factors on physicochemical and biopharmaceutical 
properties of SLMs was statistically analyzed with the aid of a central composite rotatable 
design (CCRD), response surface methodology, and numerical optimization techniques 
were applied to obtain a formulation with fine-tuned properties.
EXPERIMENTAL
Materials
NEB was a generous gift of NabiQasim Pharmaceuticals (Pvt) Ltd, Lahore, Pakistan. 
Potassium dihydrogen phosphate and Tween-20 (T-20) were purchased from Merck, Ger-
many. CW, GMS and the cellulose dialysis tube were purchased form Sigma-Aldrich, USA, 
while potassium bromide of IR grade was obtained from Fischer Scientific, UK. All chemi-
cals and reagents used were of analytical grade.
Experimental design (CCRD)
Different factors such as concentration, type of lipid, microencapsulation technique, 
concentration and type of surfactant, stirring speed and stirring time affect the yield and 
features of SLMs. Conventional experimentation for optimization needs variation of one 
variable while keeping all others at a constant level, which may lack elaboration of interac-
tions of different variables at the same time and also cause excessive consumption of time 
and excipients. The effect of different controlled independent factors on different respons-
es/features of a formulation can be studied effectively with the help of Central composite 
Rotatable Design (CCRD), which is a statistical procedure for optimization of formulations 
and is usually employed using software like Design Expert (version 8.0.6.1 Stat-ease, Inc.). 
CCRD also suggests a model equation for a specific response as a function of various con-
trolled independent variables (17–18).
In this study, formulation factors investigated for their impact on various responses 
of SLMs were CW concentration (X1), GMS concentration (X2) and T-20 concentration (X3), 
as shown in Table I. Dependent variables (responses) for this study include percentage 
yield (Y1), entrapment efficiency (Y2) and drug release at 12 h (Y3). Statistical software (De-
sign Expert) generated representative combinations of these three factors at five levels and 
the entire design consisted of 20 runs of experiments (15) with factorial (8), axial (6) and 
central (6) points (Table I). Some preliminary trials were performed in order to identify 
appropriate levels of all investigated factors (independent variables) before applying the 
design.
Preparation of SLMs (solvent evaporation method)
NEB-loaded SLMs were prepared by the solvent evaporation method. GMS and CW 
were dissolved in 50 mL of chloroform and then NEB was dissolved in this solution of solid 
lipids. The prepared lipid solution was added to a premade hot aqueous solution of T-20, 
maintained at 75 °C and homogenized at 3000 rpm for 2 hours. The resulting pre-emulsion 
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was poured into cold water (1–4 °C) and stirred with a magnetic stirrer. SLMs were allowed 
to recrystallize at room temperature, filtered using a 0.45 µm filter paper and dried using a 
desiccator. Every formulation was prepared three times and the same procedure was re-
peated to yield all formulations by varying three variables, as shown in Table I. The aqueous 
phase volume (250 mL) and the amount of the drug (10 mg) were kept constant (19).
Characterization of SLMs
Rheological studies. – Rheological studies concern evaluation of flow properties of SLM 
formulations. Appropriate flow behavior of SLMs is mandatory if SLMs are to be converted 
into tablets, capsules or some other dosage form. These studies included evaluation of bulk 
density, tapped density, Carr’s compressibility index (CI), Hausner’s ratio (HI) and angle of 
repose (AR).
Bulk density. – For bulk density (rb) calculation, the bulk volume (Vb) occupied by a 
pre-weighed amount of SLMs (m) was observed from a graduated cylinder. Bulk density 
was calculated with the help of the following formula (4, 19):





where Vb is the bulk volume and m is the mass of SLMs.
Tapped density. – For tapped density measurement, a graduated cylinder having a pre-
weighed amount of SLMs was tapped for a specified number of tapings so that SLMs at-
tained a plateau condition. The tapped volume (Vt) occupied by SLMs after tapping was 
observed (4, 19). Calculation of tapped density (rt) was performed using the of following 
formula;





where Vt is the tapped volume of SLMs.
Carr’s compressibility index. – The compressibility index (CI) of SLMs is also an indica-
tor of flow behavior and was determined with the following formula (19).






The value of Carr’s index from 12–19 % indicates a good flow character, while its value 
higher than 21 % suggests poor flow properties.
Hausner’s ratio. – Hausner’s ratio is the ratio of tapped density to bulk density of a 
material. It was also applied to calculate the flow behavior of SLMs.






where rt is the tapped density and rb represents the bulk density of SLMs. The ratio high-
er than 1.25 shows poor flow behavior and its value lower than 1.25 indicates good flow 
properties (19).
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Angle of repose. – A specified amount of SLMs was passed through a funnel on a plain 
sheet of paper. The falling SLMs made a heap on the sheet of paper. The height (h) and 
radius (r) of the heap were measured and these values were used to determine the angle 
of repose with the help of the following formula:
 tanq = h/r (5)
Free flow behavior of SLMs is confirmed if the angle of repose value is less than 30° 
(19).
Percentage yield 
To calculate percentage yield (PY), a mass of finally prepared and dried SLMs was 
taken and the obtained mass was divided by the total amount of all solid lipid components 
used to prepare SLMs (20).
Entrapment efficiency and drug loading
The amount of NEB entrapped in SLMs was also calculated. For this purpose, a speci-
fied amount of SLMs was crushed in a mortar and then dispersed in phosphate buffer 
(pH 7.4) for 24 h under continuous stirring. The solution was diluted up to 5 times by the 
use of phosphate buffer (pH 7.4) after filtration. Absorbance was measured at 286 nm using 
a UV-visible spectrophotometer (Pharma Spec 1700 Shimadzu, Japan). Calculations of the 
drug amount encapsulated (EE) in SLMs and drug loading (DL) were performed using the 
following formulas (20).
 EE = (Actual drug amount / Initial drug amount added in formulation) × 100 (6)
 DL = (Quantity of the drug in SLMs / mass of SLMs) × 100 (7)
In vitro drug release
In vitro drug release studies of all formulations were executed with the aid of a USP 
type-II apparatus (PT-DT7, Pharma Test Germany) in 0.1 mol L–1 HCl (pH 1.2) and in phos-
phate buffer (pH 6.8) as dissolution media at 37 ± 0.5 °C at a rotation speed of 50 rpm. For 
every formulation, including the optimized ones, a sample of SLMs equivalent to 5 mg of 
NEB was placed into a cellulose dialysis tube containing 5 mL of dissolution medium. The 
dialysis tube was then attached to a paddle to maintain the sink condition in the dissolu-
tion vessel containing 900 mL of dissolution medium. After a specified time interval, a 5 
mL sample was withdrawn from each dissolution vessel and an equal volume (5 mL) of 
freshly prepared and pre-warmed (37 °C) dissolution medium was added into the same 
vessel. The obtained dissolution samples were diluted up to 100 times with distilled water 
and absorbance of the diluted sample was measured at 286 nm to determine the content of 
NEB in SLMs (2, 20).The study was carried out for 2 h at pH 1.2 and for 12 h at pH 6.8. The 
drug release study included all the designed formulations and one optimized formulation 
in triplicate.
447
M. Hanif et al.: A Sustained release biodegradable solid lipid microparticles: Formulation, evaluation and statistical optimization by 
response surface methodology, Acta Pharm. 67 (2017) 441–461.
 
Drug release data analysis
To study the drug release mechanism, the drug release data of all formulations were 
further analyzed with the help of different kinetics models such as zero order, first order, 
Korsmeyer-Peppas, Hixson-Crowell and Higuchi’s models as follows (2, 20):
 Ft = K0t (8)
 logF = logF0 – Kt/2 × 303  (9)
 F = KHt
1 2/  (10)
 
1 3 1 3
0 t
/ /
HCF F K t− = ×  (11)
 3
t nM K t
M∞
=  (12)
Zero and first order rate constants are denoted K0 and K1, respectively. Similarly, KH and 
KHC represent the Higuchi and Hixson-Crowell rate constants. Drug concentration at time t 
was denoted F/Ft, and the initial drug concentration was marked F0. K3 denotes the Korsmey-
er-Peppas rate constant while n represents an exponent of the drug release mechanism. The 
value of n lower than 0.43 shows the Fickian mechanism while the value of n higher than 
0.43 and lower than 0.85 indicates the non-Fickian drug release mechanism. The value of n 
higher than 0.85 suggests slow erosion plus a diffusion drug release mechanism (20–21).
Fourier transform infrared spectroscopy (FTIR)
Compatibility of NEB with CW and GMS was analyzed with the help of an FTIR 
spectrophotometer (IR Prestage 21 Shimadzu). The FTIR spectra of the drug, CW, GMS and 
the drug loaded optimized formulation were recorded using KBr pellets, with the scan-
ning range of 4000 to 400 cm–1, at a 2 cm–1resolution. Hydraulic pressure of 150 kg cm–2 was 
used in the study (4–5).
Differential scanning calorimetry (DSC)
Drug-polymer interaction can be also performed with the help of a Thermal analyzer 
(SDT Q600 TA USA). The DSC analysis of NEB, CW, GMS and NEB-loaded optimized 
formulation was performed on an SDT-Q600 TA USA to examine any possible drug-lipid 
matrix interaction. CW, GMS, NEB and NEB-loaded SLMs were finely triturated and the 
prepared samples were then heated at a heating rate of 10 °C/min from 0 to 240 °C in a 
sealed aluminium pan. Nitrogen flow was maintained at 20 mL min–1. Reproducibility of 
the results was checked by running every sample in triplicate (4–5).
X-ray powder diffraction studies
X-ray diffraction studies were conducted with the intention to observe the impact of 
the microencapsulation process on NEB crystallinity (5). The samples were subjected to 
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irradiation with monochromatized X-rays of Cu-Kα having a voltage of 40 kV using a D-8 
advance X-ray diffractometer (Bruker AXS, USA) at a 40 mA current. Scanning of samples 
such as NEB alone, CW alone, GMS alone and of the optimized formulation of drug loaded 
SLMs (OF1) was conducted at a scan rate of 2 ° min–1 at the diffraction angle (2θ) ranging 
from 0 to 45° (4–5, 21).
Scanning electron microscopy (SEM)
The shape and surface morphology of the optimized SLMs formulation and the for-
mulation showing maximum drug release at 12 h were examined using a scanning elec-
tron microscope (JSM-840, Joel Instruments, Tokyo, Japan). The SLM sample was posi-
tioned on a double adhesive tape in the form of drops and the adhesive tape was then stuck 
to an aluminum stub. After complete evaporation from this prepared sample, gold coating 
of stubs was conducted to make them electrically conductive under an argon atmosphere. 
Photomicrographs of SLMs were obtained at 500x magnification at 10 kV (4–5).
Zeta-potential and particle size measurements
Measurement of the charge over the surface of finely prepared NEB-loaded optimized 
SLMs was performed by evaluating their electrophoretic mobility in a U-shaped tube at 25 
°C using a Malvern Zetasizer (Zetasizer Ver System; Malvern Instruments Ltd., UK). Aver-
age size and size distribution of drug loaded SLMs were also determined and for this 
purpose, SLMs were added in a cuvette containing deionized water, which was then 
placed in the Zetasizer for size measurement (4–5, 21).
Data analysis and validation
With the aid of ANOVA provided in the Design-Expert software, each suggested poly-
nomial equation and model for each response was validated statistically. The suggested 
model for each response was further analyzed on the basis of values of the predicted re-
sidual sum of squares (PRESS), multiple correlation coefficient (R2), adjusted multiple cor-
relation coefficient (adjusted R2), and coefficient of variation (CV). The level of significance 
was set at 0.05. Two dimensional contour and 3D surface plots were plotted to assess the 
effects of independent variables on dependent variables (17–18). Comparison was also 
made between experimental and predicted values. The responses followed the quadratic 
model and the suggested equation is given below:
 Y = b0  + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b11X1
2  + b22X2
2  + b33X3
2 (13)
where Y denotes the studied dependent response. Intercept b0 represents the average of all 
outcomes from 20 runs while regression coefficients (b1 to b33) were the calculated average 
values of response Y by changing one factor alone and changing two factors at the same 
time. Coded levels of independent factors were denoted X1, X2 and X3, indicating average 
values of the response obtained from changing one factor from the low to high level. In-
teraction terms for a combination of factors were denoted X1X2, X2X3, X1X3 and they indi-
cated the average change in response that occurred due to the change of two factors at the 
same time (21). A negative or a positive sign showed the antagonistic or synergetic impact 
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of the factor/factors on the response. To get an optimized formulation, help was also sought 
of the desirability approach, numerical and graphical optimization tools to create optimal 
settings for SLM formulations. The suggested optimized formulation was not only formu-
lated but also evaluated (21–22).
RESULTS AND DISCUSSION
Rheological properties
Flow behavior of the prepared SLMs was analyzed and the outcomes of rheological 
analysis are given in Table I. There was no significant difference in flow properties bet-
ween the SLM formulations; however, the wax-surfactant ratio influenced the rheology of 
SLMs. Higher surfactant concentration with lower lipid matrix concentration had a posi-
tive effect on the flow behavior of SLMs because such formulations had smoother and 
spherical shapes. The results of Carr’s index for all SLMs ranged from 12 to 18, demonstrat-
ing a good flow character of SLMs. Outcomes obtained from the angle of repose remained 
lower than 25, which also corroborated the good flow character of SLMs. Similar findings 
observed from the results of Hausner’s ratio confirmed the good rheological behavior of 
SLMs (19). It remained below 1.5 for all formulations.
Data optimization and model validation
A mathematical relationship was established between the independent factors X1 (CW 
concentration), X2 (GMS concentration) and X3 (T-20 concentration) and responses Y1 (PY), 
Y2 (EE), Y3 (DR12) and polynomial equations representing the impacts of these factors alone 
and their interactions on responses were obtained. Independent factors were those varied 
to test and check changes in dependent variables (responses) and the effects on dependent 
variables were measured and recorded. The ranges of responses (Table I) Y1, Y2 and Y3 were 
29–86, 45–83 and 48–86 %, respectively, and the ratio of maximum to minimum for the 
studied responses (Y1 = 2.96, Y2 = 1.84 and Y3 = 1.79) was found to be lower than three. In 
such a case, no further transformation of the model is suggested and power transformation 
may have little effect. The applied CCRD design suggested that all of the studied respons-
es followed a quadratic model. Significance of the quadratic model was analyzed with the 
aid of analysis of variance (ANOVA) applied at the 5 % significance level and a p-value 
lower than 0.05 indicated that the model was significant. The selected model was further 
assessed for the lack of fit (LOF) and for the studied responses; LOF was not found to be 
significant (21–22). The values of R2, adjusted R2, predicted R2, SD, % CV (Table II) and the 
analysis of variance results for each response (ANOVA) in Table II confirmed that the 
model was significant for the three studied responses. The predicted R2 values for Y1, Y2 
and Y3 of 0.7896, 0.7715 and 0.7589 were found to be very close to adjusted R2 values of Y1 
(0.8334) and Y2 (0.8425) and Y3 (0.8436), respectively (Table II). The signal to noise ratio was 
measured with adequate precision and its values for Y1 (19.396), Y2 (13.634) and Y3 (12.036) 
were found to be higher than 4, indicating the adequacy and suitability of the model for 
the studied responses (23–24).
For every SLMs formulation, the results of percentage yield (Table I) showed signifi-
cant variation from 29 (F9) to 86 % (F20). Higher concentration of CW or GMS along with 
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lower T-20 (F1, F8, F9, F12) showed lower than 50 % percentage yield. Lower yield of SLMs 
may be associated with higher aggregation of wax because of poorer stabilization of lipid 
droplets at lower concentrations of T-20. Higher concentrations of the lipid matrix along 
with higher T-20 (F3, F16) concentration were found to be good formulation parameters, 
because PY higher than 75 % was observed in these formulations (12). Similar findings were 
published in literature for biodegradable microparticulate systems (11–13). With a similar 
concentration of T-20, higher PY (53 %) was observed for the formulations containing high-
er CW concentrations (F12) compared to the formulations (F1; PY of 32 %) with higher GMS 
concentrations. The equation obtained for Y1with actual values is shown below:
 Y1 = +133.56 – 52.33X1 – 75.39X2 – 47.73X3 + 9.28X1X2 + 9.20X1X3 + 18.80X2X3  
 
 + 14.36X1
2 + 15.61X 2
2  + 21.65X3
2   (14)
For Y1, all the three factors alone had a negative impact on PY, indicating that an in-
crease in concentration of either lipids or surfactant could not increase the PY. The F-value 
for Y1 was found to be 12.54, indicating that the model was significant (p < 0.0001). Simi-
larly, the „Prob > F“ at a level of less than 0.05 showed that model terms were also signifi-
cant (24). For Y1, the p-values of X1, X3, X1 X3 were < 0.0001, showing that the CW concentra-
tion, surfactant concentration and CW with surfactant were the most significant terms. 
This suggests that both lipids alone could not formulate SLMs in the absence of T-20. The 
interaction of lipids with T-20 was found to be synergistic, causing an increase in PY of 
SLMs. Three dimensional surface graphs indicating the interaction effect of two factors 
keeping the third factor at a constant level like the impact of X1-X3 on Y1 are presented in 
Fig. 1a-c. The actual values of response Y1 were found to be very close to the predicted 
values of Y1.
Surfactant concentration played a vital role in the development and stabilization of 
droplets in emulsion, which finally contributed to the increase in PY of SLMs. At lower 
surfactant concentrations, the yield remained very low and increased lipid concentration 
with lower surfactant concentration caused more aggregation and accumulation of lipids 
instead of SLM production (2–3).
Responses Y2 and Y3 also followed a quadratic model and suggested regression equa-
tions for both responses are given below:
 Y2 = +89.76 – 20.45X1 – 37.29X2 – 26.69X3 – 0.97X1X2 + 6.00X1X3 + 9.20X2X3 
 
 + 7.09X1
2  + 11.17X2
2  + 16.03X3
2  (15)
 Y3 = +91.23 – 16.17X1 – 1.32X2 – 19.1323 – 0.65X1X2 – 3.20X1X3 – 6.40X2X3 
 
 + 6.47X1
2  + 6.45X2
2  + 10.09X3
2
The application of ANOVA to statistically validate the polynomial equations and the 
model for Y2 and Y3 suggested a level of significance (p) less than 0.05, indicating that these 
equations could be applied to forecasting the effects of all variables on the EE and drug 
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release at 12 h. The F-values for Y2 and Y3 were found to be 12.36 and 13.65, respectively, 
indicating that the model was significant (p < 0.0001). It can be concluded from the regres-
sion equation that the EE and drug release from prepared SLMs were strongly dependent 
on the studied variables (19, 22).
Assessment of EE for every SLM formulation showed great variation, from 45 (F1, F10) 
to 83 % (F19) (Table I). The percent drug loading (DL) varied from 14 (F1) to 45 % (F16). The 
EE and DL increased with an increase in lipid matrix concentration providing an equal 
increase in T-20 concentration as observed for F2, F3, F10 and F16. Formulations F3 and F9 
had equal concentrations of CW and GMS but both formulations had different EE and DL 
because of the T-20 concentration difference applied in the preparation of these formula-
tions (26). Formulations with lower percentage of CW or GMS at lower concentration of 
T-20 (F1, F12) showed minimum EE. Higher concentration of CW or GMS could not in-
crease EE as observed for F8, F9 (46 and 45 %) because a small amount of T-20 (0.16 and 0.50 
%) was available to solidify lipid droplets for the entrapment of NEB. Thus, increase in EE 
and DL depended on both the enhancement of CW/GMS concentration and surfactant T-20 
concentration. It is suggested that higher concentration of T-20 not only prevented a loss of 
drug in the external phase but was also responsible for the stabilization of lipid micropar-
ticles in the external phase.
Fig. 1. 3D response surface plots showing the effect of carnauba wax (X1), glyceryl monostearate con-
centrations (X2) and surfactant concentrations (X3) alone and in combination on percent yield (Y1) 
(a-c), on entrapment efficiency (Y2) (d-f) and on drug release at 12 h (Y3) (g-i).
a)                                                  b)                                                 c)
 
 





g)                                                  h)                                                 i)
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Significant terms observed for Y2 and Y3 were X1, X2, X3, X12, X32, indicating their po-
tential impact on EE and drug release. For Y2, X1X2, X12, X32, and X2
2  had a positive impact 
on EE, indicating that increase in CW and GMS concentration caused an increase in EE if 
there was an equal increase in T-20 concentration. Moreover, combination of lipids also 
had a negative impact on Y2 (EE), which might be due to the inability of T-20 concentration 
to emulsify and solidify SLMs droplets. Interaction of CW and GMS with T-20 was found 
to be positive, indicating a synergistic impact of T-20 on lipids to enhance EE.
Owing to their insoluble nature, lipids remain optimal materials for designing con-
trolled release drug delivery systems. Drug release graphs (Fig. 2) showed that the time of 
NEB release was strongly associated with lipid concentration (2). For Y3, lower concentra-
tion of all three variables had a negative impact on drug release while higher concentration 
of these variables had a positive influence on drug release. It was thus concluded that an 
increase in CW/GMS concentration could successfully retard drug release over 12 hours. 
The equation suggested that the effect of X1 (CW) in decreasing the release rate was found 
to be better compared to X2 (GMS). For a similar concentration of T-20, the formulation with 
higher CW concentration (F12) showed more sustained and controlled drug release com-
pared to formulations containing higher GMS concentrations (F1). The above fact could be 
associated with higher molecular weight and the more hydrophobic character of CW com-
pared to GM, which caused greater reduction in medium diffusion inside SLMs. Similarly, 
the interaction terms (X1X3) and (X2X3) were found to be negative, suggesting that the in-
teraction of CW and GMS with T-20 was useful in decreasing/controlling the NEB release. 
Moreover, drug release studies at the gastric pH of 1.2 showed less than 10 % of NEB re-
lease, suggesting a gastro protective effect of lipids due to their insoluble nature, as also 
mentioned in the literature (26).
SLMs formed at lower surfactant concentration released the drug faster compared to 
SLMs formed at higher surfactant concentration (4). This may be due to the fact that SLMs 
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S s for e  at lo er s rfacta t co ce tratio  release  t e r g faster co are  to 
S s for e  at ig er s rfacta t co ce tratio  (4). is ay be e to t e fact t at S s 
Fig. 2. Cumulative drug release profiles (%) of F1-F5 (A), F5-F10 (B), F11-F15 (C) and F16-F20 (D) at pH 6.8.Fig. 2. u ulative drug release profiles ( ) of F1-F5 ( ), F5-F10 (B), F11-F15 ( ) and F16-F20 ( ) at p  6.8.
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formed at lower surfactant concentration could have cracks and holes on the surface caus-
ing faster drug release like in the case of formulation F8 (drug release at 12 h 86 %; Fig. 4b). 
Higher concentration of lipids induces a higher hydrophobic character and decreases wa-
ter diffusion in the lipid matrix, leading towards a slower drug release rate (1). Formulation 
F19 showed very slow drug release rates because of the presence of higher lipid (CW) con-
Fig. 3. DSC thermograms of nebivolol (A), carnauba wax (B), glyceryl monostearate (C), mixture of 
carnauba wax and glyceryl monostearate (D), optimized formulation of nebivolol-loaded SLMs (E). 
FTIR spectra of nebivolol (A), carnauba wax (B), glyceryl monostearate (C), mixture of carnauba wax 
and glyceryl monostearate (D), optimized formulation of nebivolol-loaded SLMs (E) and XRD Pat-
terns of nebivolol (A), carnauba wax (B), glyceryl monostearate (C), blank SLMs (D) optimized formu-
lation of nebivolol-loaded SLMs (E).
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Fig. 4. SEM photomicrographs of the: a) optimized formulation, b) SEM image of formulation F8, c) 
particle size distribution curve and d) zeta-potential distribution curve of the optimized formulation.
   a)                                          b)                                c)                               d)
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particle size distribution curve and d) zeta-potential distribution curve of the opti ized for ulation.
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centration. Interaction effects of CW concentration (X1) and GMS (X2) on Y2 and Y3 are 
shown in Fig. 1d-i.
Impacts of CW, GMS and T-20 concentration were found to be significant for all of the 
studied responses and the impact of CW and T-20 could be considered more prominent 
compared to that of GMS on the studied responses. In polynomial equations, the coeffi-
cients for interaction terms (combination of variables) were found to be positive, indicating 
a synergistic effect of variables on responses. For response Y3, it was objective to decrease 
the drug release over 12 hours. It was observed that CW had a more prominent effect than 
that of GMS. It was also observed that the connection between variables and observed 
responses was not linear. Furthermore, a change of more than one variable at the same 
time at different levels produced quite a different intensity of the response (24, 26).
The numerical optimization technique was applied to set optimum conditions of the 
process variables (X1, X2, X3) for attaining desirable results for responses Y1, Y2 and Y3 of 
SLM formulations. Desirability of the studied responses was calculated on a scale of 0–1 
with the aid of software and was found to be close to one (17). Selection of optimum SLM 
formulations was made on the basis of achieving maximum PY (90 %), maximum EE (85 %) 
but minimum drug release at 12 h (less than 50 %), since controlling the drug release rate 
remains a critical factor in designing sustained release drug delivery systems. The opti-
mized formulation OF1 (Table III) suggested by software was prepared and characterized 
for the responses. Comparison of the predicted and observed values of three responses for 
the optimized formulation was made and the calculated prediction error (equation 18) was 
found to be very low, as shown in Table III. It was quite obvious that polynomial equations 
sufficiently addressed the impact of independent formulation variables on the studied 
responses, suggesting adequateness and suitability of optimization techniques by CCRD 
for optimizing the SLM formulation (24–25).
 PE (%) = Observed value – Predicted value / Predicted value × 100 (16)
Drug release kinetics
Different drug release kinetic models such as zero order, first order, Korsmeyer-Pep-
pas, Hixson Crowell and Higuchi models were applied to the analyzed drug release pro-
files of prepared SLM formulations and the outcomes for release constants and regression 
coefficients are shown in Table IV. Drug release profiles dominantly followed zero order 
Table III. The suggested optimized formulation composition, predicted and observed levels of responses, 
















X1 1.75 Y1 80.86 75.8 1.04
X2 1.75 Y2 77.64 78.8 1.5 0.889
X3  1.50 Y3 51.08 46.7 1.4
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and Higuchi models because the obtained R² values for these models were found to be 
higher compared to the values of R² for the other models applied. According to the zero 
order model, the NEB release from SLMs was independent of the remaining drug concen-
tration in SLMs while the Higuchi model suggests the diffusion mechanism of drug re-
lease. The n value ranged from 0.87 to 1.07 (anomalous mechanism of drug release), sug-
gesting that drug release was not only controlled by diffusion but also erosion of 
biopolymers. Thus the likely mechanism for release of encapsulated NEB from SLMs 
would be drug diffusion from the hydrophobic lipid matrix of SLMs (20).
Fourier transform infrared spectroscopy (FTIR)
FTIR study demonstrated good compatibility of NEB with both encapsulating agents 
(CW and GMS). Individual spectra of NEB, GMS and CW were compared with the FTIR 
spectrum of the prepared drug loaded SLMs, as shown in Fig. 3 (Section FTIR). Character-
istic aliphatic N-H, alkenes C=C and C-H stretches were observed at 3185, 2319 and 1490 
cm–1, respectively, not only in the NEB spectrum but also in NEB-loaded OF1. Similarly, 
carbonyl and CO-ester groups were also visible at 1536 and 1074 cm–1, respectively, in the 
FTIR-spectrum of NEB-loaded SLMs.
The spectra of NEB alone and of NEB-loaded SLMs also indicated major stretches for 
aliphatic CH groups and alcoholic and phenolic OH groups at 2870 and 3650 cm–1, respec-
tively. FTIR spectra did not show the absence or shift of any principal peaks of NEB or CW 
or GMS either in the FTIR spectrum of NEB-loaded SLMs or in individual FTIR spectra of 
NEB, CW and GMS. These findings confirmed the compatibility of NEB and lipids used 
for the preparation of SLMs (26).
Differential scanning calorimetry (DSC)
Compatibility of NEB with CW and GMS was analyzed with the help of differential 
scanning calorimetry. DSC thermograms of NEB, CW and drug loaded SLMs are pre-
sented in Fig. 3 (Section DSC). Specific endothermic peaks relevant to melting points of CW 
and GMS were quite visible at a temperature of 85 °C for CW alone (B) and at 59 °C for GMS 
(C), as shown in Fig. 3 (Section DSC). The presence of a particular peak associated with the 
melting of NEB in drug loaded SLMs at a temperature of 221 °C was also confirmed. How-
ever, a decrease in peak intensity and lowering of the NEB melting peak temperature in-
dicated that some fraction of NEB still existed in crystalline form in the prepared SLMs 
(E). Similarly, in NEB-loaded SLMs, particular peaks corresponding to CW and GMS melt-
ing points were also visible at temperatures of 85 and 59 °C, respectively, showing compat-
ibility of the lipids and the drug (4, 26). All of these observations clearly support the fact of 
NEB inclusion in the prepared SLMs.
X-ray power diffraction studies
X-ray power diffraction studies of optimized formulations were performed and the 
XRD patterns of individual drugs (3A of section XRD), individual lipids (3B and 3C of sec-
tion XRD), blank SLMs (3D of section XRD) and prepared NEB-loaded optimized SLMs (3E 
of section XRD) were compared for any addition or deletion of typical components (Fig. 3 
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XRD). The comparison indicated the presence of characteristic NEB peaks (Fig. 3E) without 
any impact on the diffraction position. However, a reduction in the intensity of NEB peaks 
indicated that some of the drug was still in crystalline form in SLMs. The XRD examina-
tion of NEB-loaded SLMs (Fig. 3E of section XRD) revealed sharp as well as scattered 
peaks, proving that a fraction of NEB was changed into amorphous form while formulat-
ing SLMs. This change in crystallinity may also cause drug expulsion and may alter the 
drug release rate (28). The peaks for NEB were observed at 2θ of 20°, 25° and 30°, indicating 
the crystalline nature of NEB (Fig. 3A). There was complete absence of any prominent al-
teration in the diffraction position relevant to NEB, suggesting that formulation steps of 
NEB-loaded SLMs did not produce any unfavorable effects on NEB (7). Moreover, the 
smoothness of lipid peaks in Fig. 3D and 3E indicated formation of NEB-loaded SLMs.
Scanning electron microscopy (SEM)
The prepared SLMs of the optimized formulation (OF1) were found to be spherical in 
shape, as shown in Fig. 4a. Most of the studies in literature have also reported the spherical 
shape of solid lipid microparticles (27). The surface of SLMs made with higher T-20 con-
centrations was found to be smooth because at higher level of T-20, lipid droplets could 
solidify better and yield spherical smooth surfaced SLMs (19). At the same time, holes in 
the surface of SLMs of OF1 made with higher lipid concentration were quite invisible (2, 
5). The absence of these holes facilitated controlled release of NEB from SLMs. The SEM 
image (Fig. 4b) of formulation (F8) with maximum drug release (86 %) clearly indicated the 
presence of holes and a rough surface, which may be attributed to minimum concentration 
of T-20 that could not emulsify and solidify lipid droplets properly. SEM studies also indi-
cated that the optimized SLMs had an average size of 40 µm.
Zeta-potential and particle size measurements
The particle size distribution and zeta-potential of the optimized formulation (OF1) 
were determined with the help of the electrophoretic light scattering method (Fig. 4c and 
4d, respectively). Size distribution of SLMs ranged from 10 to 40 µm while the major frac-
tion of SLMs had an average size of 25 µm. Particle size was greatly influenced by the 
concentration of lipids and concentration of T-20 (28). Formulation OF1 showing smaller 
size and a narrow size distribution because T-20 at a concentration level of 1.75 % m/V 
greatly contributed to the yield of micron size SLMs as SLM preparation without surfac-
tant during the preliminary stage failed. Higher T-20 concentration played a role in pre-
venting the aggregation of hydrophobic lipid microparticles (19–20).
Stabilty of SLMs was deduced from the measurement of zeta-potential, which is the 
electrical/charge potential at the shear plane. Particles with higher zeta-potential would 
prevent microparticle aggregation due to higher interparticle repulsion and could be re-
garded as having better storage stability. In the current study, the zeta-potential of OF1 was 
observed in the range of –20 to –40 mV (Fig. 4c), indicating that SLMs should have better 
stability. Minimum value of 30 mV is usually necessory for better stability of SLMs (28). 
Similar findings from Mishara et al. (2009) are reported in literature (28). The presence of 
high intensity of negative charge would generate electrostatic repulsion between SLMs, 
disallowing aggregation of SLMs (25). The negative zeta-potential value of optimized 
458
M. Hanif et al.: A Sustained release biodegradable solid lipid microparticles: Formulation, evaluation and statistical optimization by 



























































































































































































































































































































































































































































































































































































































































































































































































M. Hanif et al.: A Sustained release biodegradable solid lipid microparticles: Formulation, evaluation and statistical optimization by 
response surface methodology, Acta Pharm. 67 (2017) 441–461.
 
SLMs was expected because formulation ingredients like CW consist of aliphatic esters, 
ester of 4-hydroxycinnamic acid, hydroxycarboxylic acid, fatty alcohols and GMS consists 
of glycerol esters of fatty acid. T-20 is a type of non-ionic surfactant and is considered neu-
tral and not able to increase the zeta-potential values. Such results were obtained for NLC 
prepared with the same wax and surfactant but loaded with benzophenone-3 (29). The 
presence of free fatty acids in lipids and emulsifier such as T-20 may contribute negative 
charge to SLMs because the manufacturing of T-20 and other surfactants involves free 
fatty acids as substrate (29).
CONCLUSIONS
NEB loaded SLMs were successfully formulated by the solvent evaporation method 
and then characterized for rheological behavior, zeta size, zeta potential and morphology. 
With the help of a central composite rotatable design (CCRD), concentration levels of the 
selected formulation parameters such as CW concentration (1.75 %, m/m), GMS concentra-
tion (1.75 %, m/m) and surfactant concentration (1.50 %, m/m) were optimized with the in-
tention to achieve minimum drug release and maximum percentage yield and entrapment 
efficiency. The optimized SLM formulation (OF1) showed 46 % drug release after 12 h, 75 
% percentage yield and 78 % entrapment efficiency. Smooth, spherical, free flowing SLMs 
with a size range of 10 to 40 µm and a zeta-potential of –20 to –40 mV were formulated. 
FTIR and DSC analysis confirmed compatibility of the drug with lipids. Powder X-RD 
studies showed that the drug retained its crystalline form during the encapsulation pro-
cess. Drug release kinetics indicated the Higuchi drug release model with a possible mech-
anism of erosion and diffusion, as shown from the value of n > 0.85. CW and GMS proved 
to be suitable release retarding materials. CW was found to be a better carrier than GMS 
for achieving desired responses in the prepared sustained release SLMs but the role of T-20 
was found to be a much more critical factor compared to the other two variables. Further-
more, sustained release SLMs loaded with NEB could offer possible benefits of controlling 
the heart rate for 24 hours in patients with chronic hypertension and could be helpful in 
minimizing side effects and treatment costs.
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